

SEATTLE GENETICS INC /WA  
Form 8-K  
July 09, 2003

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

Current Report Pursuant to Section 13 or 15(d) of The  
Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): July 8, 2003**

**Date of Filing: July 8, 2003**

**Seattle Genetics, Inc.**

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**0-32405**  
(Commission File Number)

**91-1874389**  
(I.R.S. Employer  
Identification No.)

**21823 30<sup>th</sup> Drive SE**

**Bothell, Washington 98021**

(Address of principal executive offices, including zip code)

**(425) 527-4000**

Edgar Filing: SEATTLE GENETICS INC /WA - Form 8-K

(Registrant's telephone number, including area code)

**Item 9. Regulation FD Disclosure**

On July 8, 2003, Seattle Genetics, Inc. completed a \$41 million private placement transaction in which the company issued 1,640,000 shares of Series A convertible preferred stock, which are convertible into 16.4 million shares of common stock, and warrants to purchase 2,050,000 shares of common stock. J.P. Morgan Partners and Baker Brothers Investments led the private placement, with additional participation by Delphi Ventures, BA Venture Partners and T. Rowe Price Health Sciences Fund, Inc. As of closing, Srinivas Akkaraju, M.D., Ph.D. and Felix Baker, Ph.D. were appointed to Seattle Genetics' board of directors, thereby increasing the size of the board to nine directors.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**SEATTLE GENETICS, INC.**  
(Registrant)

Date: July 8, 2003

By:

/s/ Tim Carroll

---

Tim Carroll  
Chief Financial Officer